A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

Trial Profile

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-177
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 04 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 18 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
    • 06 Dec 2017 Planned number of patients changed from 270 to 300.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top